Alpharma Pharms Drug Patent Portfolio
Alpharma Pharms owns 1 orange book drug protected by 9 US patents Given below is the list of Alpharma Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8623418 | Pharmaceutical composition | 07 Nov, 2029 | Active |
US7815934 | Sequestering subunit and related compositions and methods | 12 Dec, 2027 | Active |
US7682633 | Pharmaceutical composition | 19 Jun, 2027 | Active |
US7682634 | Pharmaceutical compositions | 19 Jun, 2027 | Active |
US8158156 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist | 19 Jun, 2027 | Active |
US8846104 | Pharmaceutical compositions for the deterrence and/or prevention of abuse | 19 Jun, 2027 | Active |
US8877247 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist | 19 Jun, 2027 | Active |
US8685443 | Sequestering subunit and related compositions and methods | 03 Jul, 2025 | Active |
US8685444 | Sequestering subunit and related compositions and methods | 03 Jul, 2025 | Active |
Latest Legal Activities on Alpharma Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alpharma Pharms.
Activity | Date | Patent Number |
---|---|---|
Expire Patent
Critical
| 20 May, 2024 | US8158156 |
Maintenance Fee Reminder Mailed
Critical
| 04 Dec, 2023 | US8158156 |
Expire Patent
Critical
| 12 Dec, 2022 | US8877247 |
Expire Patent
Critical
| 21 Nov, 2022 | US7815934 (Litigated) |
Expire Patent
Critical
| 07 Nov, 2022 | US8846104 |
Maintenance Fee Reminder Mailed
Critical
| 27 Jun, 2022 | US8877247 |
Maintenance Fee Reminder Mailed
Critical
| 06 Jun, 2022 | US7815934 (Litigated) |
Maintenance Fee Reminder Mailed
Critical
| 23 May, 2022 | US8846104 |
Expire Patent
Critical
| 25 Apr, 2022 | US7682633 (Litigated) |
Expire Patent
Critical
| 25 Apr, 2022 | US7682634 (Litigated) |
Maintenance Fee Reminder Mailed
Critical
| 08 Nov, 2021 | US7682633 (Litigated) |
Maintenance Fee Reminder Mailed
Critical
| 08 Nov, 2021 | US7682634 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 16 Sep, 2019 | US8158156 |
Payment of Maintenance Fee, 4th Year, Large Entity | 13 Apr, 2018 | US8877247 |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Mar, 2018 | US7815934 (Litigated) |
Alpharma Pharms's Family Patents
Alpharma Pharms drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 25.3% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Alpharma Pharms Drug List
Given below is the complete list of Alpharma Pharms's drugs and the patents protecting them.
1. Embeda
Embeda is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8623418 | Pharmaceutical composition |
07 Nov, 2029
(5 years from now)
| Active |
US7815934 | Sequestering subunit and related compositions and methods |
12 Dec, 2027
(3 years from now)
| Active |
US7682633 | Pharmaceutical composition |
19 Jun, 2027
(2 years from now)
| Active |
US7682634 | Pharmaceutical compositions |
19 Jun, 2027
(2 years from now)
| Active |
US8158156 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
19 Jun, 2027
(2 years from now)
| Active |
US8846104 | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
19 Jun, 2027
(2 years from now)
| Active |
US8877247 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
19 Jun, 2027
(2 years from now)
| Active |
US8685443 | Sequestering subunit and related compositions and methods |
03 Jul, 2025
(8 months from now)
| Active |
US8685444 | Sequestering subunit and related compositions and methods |
03 Jul, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Embeda's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List